|Day Low/High||23.91 / 24.20|
|52 Wk Low/High||10.85 / 33.82|
Following up on a pledge to accelerate generic drugs into the marketplace to stoke price competition, the agency signals pending reform of the Risk Evaluation and Mitigation Strategy.
Jim Cramer weighs in on Sirius XM Radio, Teva Pharmaceuticals, iQIYI, Blue Apron, Shopify, Incyte, E*Trade Financial and more.
Jim Cramer tells investors to keep their eyes open for companies making changes -- that's what's being rewarded.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today confirmed that the U.
Here's what you need to know now for Friday, May 18.
Aimovig is the first treatment approved by the agency to prevent migraines by blocking the calcitonin gene-related peptide receptor.
The Dow, S&P 500 and Nasdaq all rose on Wednesday.
Berkshire Hathaway hiked its stake in the drugmaker, which is undergoing a restructuring, to 40.5 million shares as of the end of March.
First bulleted paragraph, second sentence of release dated May 15, 2018 should contain the numbers 4.
The Israel-based drugmaker reported first-quarter numbers that surpassed analysts' expectations but Wall Street wants to see more.
Shares of Tesla Inc., which reported earnings on Wednesday, fell by 5.5%
Teva shares edged into positive territory for the year Thursday after a stronger-than-expected start to the year allowed CEO Kåre Schultz to boost the generic drugmaker's 2018 earnings forecast.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended March 31, 2018.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced new scientific abstracts for AUSTEDO ® (deutetrabenazine) tablets will be presented at the American Psychiatric Association (APA) 2018 Annual Meeting in New York from May 5-9.
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced up to 7-year efficacy, safety and tolerability results from the Glatiramer Acetate Low-Frequency Administration (GALA) open-label extension study of COPAXONE ® (glatiramer...
Jim Cramer shines a spotlight on McDonald's, Nucor, Ball Corp. United States Steel, Teva Pharmaceuticals, Chicago Mercantile Exchange and more.
Jim Cramer says he's still optimistic, and he doesn't want investors to give up. But he has 12 reasons to also remain cautious -- especially about Fridays.
The tough news keeps coming at the generic drug company, which announced last week it was considering putting itself up for sale. Now the Justice Department wants a chat.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its first quarter 2018 financial results on Thursday, May 3, 2018 at 7:00 a.
Teva Pharmaceutical Industries [NYSE and TASE: TEVA] has announced that Teva and the Procter & Gamble Company [NYSE: PG] have agreed to terminate the PGT Healthcare partnership that the two companies established in 2011 to market OTC (Over The...
Procter & Gamble will pay around $4.2 billion for the consumer healthcare unit of Merck KGaA in the first major deal for the group since activist investor Nelson Peltz joined the board last month.
Following Wednesday's event, Leerink analyst Ami Fadia said she is 'incrementally more positive' on the drugmaker's pipeline and diversified business model and moved her rating to outperform.
While more than half the states in the U.S. have passed time limits on opioid prescription as a way to battle the epidemic, the AMA says that should be left up to the doctor and patient.
As President Trump tees up a set of 25% tariffs on a wide range of products against China trade, generic drug makers as well as their patients likely will be affected.
RBC's Randall Stanicky says concerns have moved from being about global generic growth to Teva's branded drug business.
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of Lialda ®1 (mesalamine) delayed-release tablets, 1.
Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced the launch of a generic version of ALOXI ®1 (palonosetron HCI) injection, 0.
Novartis subsidiary Sandoz Canada will work with cannabis producer Tilray to produce non-smokable medical cannabis products in Canada, becoming the first Big Pharma company to get into medical pot.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.